62 results
8-K
EX-99.1
WINT
Windtree Therapeutics Inc
17 Apr 24
Windtree Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Key Business Updates
7:30am
.”
“The R&D and clinical team has been busy this period. We advanced the istaroxime program in cardiogenic shock with two clinical trials. First, we
8-K
EX-99.1
WINT
Windtree Therapeutics Inc
7 Aug 23
Windtree Therapeutics Reports Second Quarter 2023 Financial Results and Provides Key Business Updates
4:02pm
million. Cash and cash equivalents as of June 30, 2023 were $11.5 million.
Hosted a virtual R&D and Investor Day on June 14, 2023, focusing
424B4
qbehzgigrfuj9nr
21 May 20
Prospectus supplement with pricing info
6:04am
8-K
EX-99.1
78h086alp
3 Apr 20
Windtree Therapeutics Reports Fourth Quarter 2019 Financial Results and Provides Key Business Updates
6:31am
8-K
EX-99.1
ik85b0yeh6zmfz
25 Oct 19
Windtree Therapeutics Provides Business Update
5:17pm
8-K/A
EX-99.1
vi496elioofonl n1os
8 Mar 19
Completion of Acquisition or Disposition of Assets
4:24pm
8-K/A
EX-99.2
y5lc 573zjmfrz04d
8 Mar 19
Completion of Acquisition or Disposition of Assets
4:24pm
8-K
0cydys9n j6vlex63
21 Dec 18
Windtree Therapeutics and CVie Therapeutics Announce Merger to Create a Global Acute Care Company Targeting Cardiovascular and Respiratory Diseases
5:28pm